August 20, 2018 / 5:12 AM / a month ago

Roche's Alecensa latest beneficiary of faster China drug approvals

ZURICH, Aug 20 (Reuters) - Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans.

China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after after European and U.S. approvals. (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below